Phase 3CompletedAge-related condition

177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer (PSMAfore)

PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer

Sponsor
Novartis Pharmaceuticals (Industry)
Enrollment
469 enrolled
Conditions
Prostatic Neoplasms
Interventions
177Lu-PSMA-617; 68Ga-PSMA-11; ARDT
Ages
adults, older adults
Registry
NCT04689828, CTIS2023-507772-50-00

Full record on ClinicalTrials.gov

From the registry

The purpose of this study is to determine whether 177Lu-PSMA-617 improves the Radiographic progression-free survival (rPFS) or Overall Survival (OS) compared to a change in Androgen receptor-directed therapy (ARDT) in metastatic castrate resistant prostate cancer (mCRPC) participants that were previously treated with an alternate ARDT and not exposed to a taxane-containing regimen in the CRPC or mHSPC settings. 469 participants were randomized (235 in the 177Lu-PSMA-617 group and 234 in the ARDT group.

Primary outcomes

  • Radiographic Progression Free Survival (rPFS)

History

  1. Last registry update

  2. Study completion

  3. Results first posted

  4. Primary completion

  5. Started

  6. Registered